Hoboken Radiology participates with the National Oncologic PET Registry (NOPR). The NOPR is a collaboration of the American College of Radiology Imaging Network (ACRIN), the American College of Radiology (ACR), and the Academy of Molecular Imaging (AMI), to ensure access to Medicare reimbursement for certain types of positron emission tomography (PET) scans.
The goal of the National Oncologic PET Registry is to assess the effect of PET with F-18 fluorodeoxyglucose (FDG) and sodium fluoride F-18 (NaF-PET) on referring physicians’ plans of intended patient management for those cancers and indications not currently eligible for reimbursement from the Centers for Medicare and Medicaid Services (CMS). Data is collected from the referring physician before and after the PET study. In order for Hoboken Radiology to be eligible for reimbursement by CMS, collection of required data must be reported to the NOPR within 30 days of the PET scan. Without our participation with the NOPR, Medicare patients would be denied approval for the above mentioned studies and be required to cover the cost of the PET themselves.
Sodium fluoride F-18 (Naf-PET) Bone Scans for the detection of osseous metastasis is currently covered through the NOPR. It is a direct replacement technology for traditional Tc-99m Radionuclide Bone Scans.
For a listing of indications (FDG only) currently covered by CMS and the NOPR click here.